Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab

BACKGROUND: The COVID-19 epidemic raises important questions about the efficacy of vaccines for people treated with ocrelizumab, an anti-CD20 therapy. Ocrelizumab has been shown to reduce the humoral response to SARS-CoV-2 infection and vaccination, but the T-cell response to vaccination has not bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Katz, J.D., Bouley, A.J., Jungquist, R.M., Douglas, E.A., O'Shea, I.L., Lathi, E.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575541/
https://www.ncbi.nlm.nih.gov/pubmed/35158475
http://dx.doi.org/10.1016/j.msard.2021.103382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575541/
https://www.ncbi.nlm.nih.gov/pubmed/35158475
http://dx.doi.org/10.1016/j.msard.2021.103382

Ejemplares similares